本年度重点实验室共发表学术论文97篇，其中SCI收录合计27篇，第一作者或通讯作者单位25篇，影响因子合计87.796，单篇最高影响因子23.259；中文期刊发表论文合计70篇，核心期刊收录70篇。

英文文章

1.       心血管病方向

[1] Li X,Shang H*, Xing Y. New risk stratification on SCN5A mutation in Brugada

syndrome. Int JCardiol. 2018, 271:123.(SCI收录,IF:4.034)......................................1

[2] Zheng R,Tian G, Zhang Q, Wu L, Xing Y, Shang H*. Clinical Safety and Efficacy ofWenxin Keli-Amiodarone Combination on Heart Failure Complicated by Ventricular Arrhythmia:A Systematic Review and Meta-analysis. Front Physiol. 2018 May 23;9:487. (SCI收录,IF: 3.394).............................................................................2

[3] Yang X, LiX, Yuan M, Tian C, Yang Y, Wang X, Zhang X, Sun Y, He T, Han S,

Chen G, Liu N,Gao Y, Hu D, Xing Y, Shang H*. Anticancer Therapy-Induced Atrial

Fibrillation:Electrophysiology and Related Mechanisms. Front Pharmacol. 2018 Oct

16;9:1058. (SCI收录,IF: 3.115)....................................................................................3

[4]Tian G, SunY, Liu S, Li C, Chen S, Qiu R, Zhang X, Li Y, Li M, Shang H*.

TherapeuticEffects of Wenxin Keli in Cardiovascular Diseases: An Experimental

and MechanismOverview. Front Pharmacol. 2018 Sep 5;9:1005.  (SCI收录,IF: 3.115)..............................................................................................................................4

[5]Li M, Li C,Chen S, Sun Y, Hu J, Zhao C, Qiu R, Zhang X, Zhang Q, Tian G,

ShangH*. Potential Effectiveness of ChinesePatent Medicine Tongxinluo Capsule

for SecondaryPrevention After Acute Myocardial Infarction: A Systematic Review

andMeta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2018 Aug

3;9:830.(SCI收录,IF: 3.115).........................................................................................5

[6]Liu S, TianG, Chen J, Zhang X, Wu A, Li M, Sun Y, Liu B, Xing Y, Shang H*.

TraditionalChinese Medicine for Bradyarrhythmia: Evidence and Potential

Mechanisms.Front Pharmacol. 2018 Apr 9;9:324. doi: 10.3389/fphar.2018.00324.

eCollection2018. PubMed PMID: 29686614; PubMed Central PMCID: PMC5900793. (SCI收录,IF:3.115).............................................................................6

[7]Li X, Yang X,Li Y, Yuan M, Tian C, Yang Y, Zhang X, Liu C, Gao Y, Liu N,

ShangH*, Xing Y. Mitochondria and thePathophysiological Mechanism of Atrial

Fibrillation.Curr Pharm Des. 2018;24(26):3055-3061. (SCI收录,IF:2.757)..............................................................................................................................7

[8]Qiu R, Li M,Zhang X, Chen S, Li C, Shang H*. Development of a core outcome

set (COS) andselecting outcome measurement instruments (OMIs) for non-valvular

atrialfibrillation in traditional Chinese medicine clinical trials: study

protocol.Trials. 2018 Oct 5;19(1):541.(SCI收录,IF:2.067)........................................8

[9] Sisi Lin,Bo Nie,Guihong Yao,Hui Yang,Ren Ye,Zhengzhong Yuan.Pinellia ternata (Thunb.) MakinoPreparation promotes sleep by increasing REM sleep.Natural ProductResearch.2018,DOI: 10.1080/14786419.2018.1474466.（SCI收录，IF1.057）...........................................................................................................................9

[10]XIAOWANHAN,AIMINGWU,JIE WANG,HONG CHANG,YIZHOU ZHAO,YAN ZHANG,YINGQIU MAO,LIXIALOU,YONGHONG GAO,DONGMEI ZHANG,TONG LI,TAO YANG,LEI WANG,CUILING FENG*,MINGJINGZHAO.*Activation and migration of adventitial fibroblasts contributes tovascular remodeling.The Anatomical Record .2018,301,1216–1223.（SCI收录，IF1.373）...........................................................................................................................10

[11]Anbang Han,Yingdong Lu,Qi Zheng,Jian Zhang ,YiZhou Zhao,Mingjing Zhao*,XiangningCui.Qiliqiangxin Attenuates Cardiac Remodeling via Inhibition of TGF-β1/Smad3 and NF-κBSignaling Pathways in a Rat Model of Myocardial.Cellular Physiology andBiochemistry .2018,45,1797-1806.（SCI收录，IF5.5）..........................................................................................................................11

2.脑血管病方向

[12]YuanM, Tian C, Li X, Yang X, Wang X, Yang Y, Liu N, Kusano KF, Barajas-Martinez H,Hu D, Shang H, Gao Y*, Xing Y*. Gender Differences in Prognosis andRisk Stratification of Brugada Syndrome: A Pooled Analysis of 4,140 PatientsFrom 24 Clinical Trials. Front Physiol. 2018 Aug 22;9:1127. （SCI收录，IF3.394）...........................................................................................................................12

[13]RenX, Wang X, Yuan M, Tian C, Li H, Yang X, Li X, Li Y, Yang Y, Liu N, Shang H, GaoY*, Xing Y*. Mechanismsand Treatments of Oxidative Stress in Atrial Fibrillation. CurrPharm Des. 2018;24(26):3062-3071.（SCI收录，IF2.757）...........13

[14]YuanM, Liu N, Wang X, Tian C, Ren X, Zhang H, Yang X, Li X, Zhu H, Zhu L, Shang H,Xing Y*, Gao Y*. The Mechanismof Exosomes Function in Neurological Diseases: A Progressive Review.Curr Pharm Des. 2018;24(24):2855-2861.（SCI收录，IF2.757）...............................................................................................................14

[15]LiJ, Wei D, Niu J, Yang M, Ge L, Wang X, Yuan W, Tian J, Shang H, Zhai J,

YangK, Dai M. Potential Facilitators and Barriers to Awareness of N-of-1 Trials

forPhysicians in Traditional Chinese Medicine. Altern Ther Health Med. 2018

Mar;24(2):44-49.（SCI收录，IF1.011）................................................................15        

3.肾脏病、内分泌、风湿免疫方向

[16]  Mengdi Wang, Zhen Wang,Jingwei Zhou1, Weiwei Sun, Ying Wang, Mei Han4, Hanwen Yang, Wei Jing Liu* and Yaoxian Wang*: Effects of traditional Chinese herbal medicine in patients with diabetickidney disease: study protocol for a randomized controlled trial. Trials 2018; 19:389.(SCI收录,IF:2.067).....................16

[17]Liu WJ#, Huang WF#, Ye L, Chen RH, Yang C, Wu H, Pan Q, Liu HF:The activity and role of autophagy in the pathogenesis of diabetic nephropathy.Eur Rev Med Pharmacol Sci, 2018 May;22(10):3182-3189.(SCI收录,IF:2.387).................17

[18]Wang D, Hu X, Lee SH, ChenF, Jiang K, Tu Z, Liu Z, Du J, Wang L, Yin C, Liao Y, Shang H, Martin KA,Herzog RI, Young LH, Qian L, Hwa J, Xiang Y. Diabetes Exacerbates MyocardialIschemia/Reperfusion Injury by Down-Regulation of MicroRNAand Up-Regulation ofO- GlcNAcylation. JACC Basic Translational Science. 2018 May16;3(3):350-362. (SCI收录,新刊入库未产生影响因子 ).........18

4.临床评价方向

[19] Chen Y,Wang C, Shang H*, Yang K, Norris SL. Clinical practice guidelines in

China. BMJ. 2018Feb 5;360:j5158. (SCI收录,IF 23.259)........................................19

[20] Li C, WangP, Zhang L, Li M, Lei X, Liu S, Feng Z, Yao Y, Chang B, Liu B,

ShangH*. Efficacy and safety of Xuebijinginjection (a Chinese patent) for

sepsis: Ameta-analysis of randomized controlled trials. J Ethnopharmacol. 2018

Oct5;224:512-521.(SCI收录,IF 3.831)......................................................................20

[21]Zhai J, MuW, Si J, Li Y, Zhao C, Shang H*, Li H, Tian G. Acupuncture for

constipation inpatients with stroke: protocol of a systematic review and

meta-analysis.BMJ Open. 2018 Mar 30;8(3).(SCI收录,IF 2.413)............................21

[22] Chen S,Kwong JSW, Zheng R, Wang Y, Shang H*. Normative Application of

XiyanpingInjection: A Systematic Review of Adverse Case Reports. Evid Based

ComplementAlternat Med. 2018 Nov 15;2018:4013912.(SCI收录,IF 2.064)............................................................................................................................22

[23]Chen YL,Zhao C, Zhang L, Li B, Wu CH, Mu W, Wang JY, Yang KH, Li YP, Chen C, Wang YY,Wang C, Bian ZX, Shang HC*. Toward Evidence-Based ChineseMedicine:Status Quo, Opportunities and Challenges. Chin J Integr Med. 2018

Mar;24(3):163-170.(SCI收录,IF1.991).....................................................................23

[24] Wang JY,Tian GH, Li YP, Wu TX, Bian ZX, Du L, Shang HC*. Systematic

Reviews/Meta-Analysesof Integrative Medicine in Chinese Need Regulation and

MonitoringUrgently and Some Suggestions for Its Solutions. Chin J Integr Med.2018Feb;24(2):83-86. (SCI收录,IF1.991)..........................................................................24

5.中药药理及作用机制方向

[25]Fangchen,Yingkun He,Pengwen Wang*,Peng Wei,Huili Feng,Yingxue Rao,JingShi,Jinzhou Tian.Banxia Xiexin decoction ameliorated cognition via the regulation of insulin pathways and glucosetransporters inthe hippocampus of APPswe/PS1dE9 mice.Int J Immunopathol Pharmacol.2018,32:1-8.（SCI收录，IF2.117）.................................................................................................................................25

[26]Yang X, LiuN, Li X, Yang Y, Wang X, Li L, Jiang L, Gao Y, Tang H, Tang Y,

Xing Y, ShangH*. A Review on the Effect of Traditional Chinese Medicine Against

Anthracycline-InducedCardiac Toxicity. Front Pharmacol. 2018 May 15;9:444.(SCI收录,IF:3.115)............................................................................................................26

[27]Qiu R, Zhang X, Zhao C, Li M, Shang H*. Comparison of the efficacy of

dispensinggranules with traditional decoction: a systematic review and

meta-analysis.Ann Transl Med. 2018 Feb;6(3):38. (SCI收录,新刊入库,未产生影响因子 ).......................................................................................................................27

备注：#：共同第一作者；*：通讯作者

中文文章

1.       心血管病方向

[1]陈慧洋，娄利霞，赵一舟，李春红，黄涯，张冬梅，王帅，侯雅竹，吴爱明*，商洪才.芪丹利心丸对心肌梗死大鼠左心室心肌组织miR-133a/TGF-β1/CTGF信号通路的影响.中医杂志，2018，59(20):1771-1776............................................28

[2]陈慧洋，娄利霞，吴爱明*.心肌细胞横管系统与钙离子稳态的相关性的研究进展，2018，16(17):2498-2501.................................................................................29

[3]李彤，赵明镜*，韩小婉，赵一舟，杨涛，王蕾，王保福，张菁，京继.血管外膜成纤维细胞在动脉粥样硬化及PCI后再狭窄中的作用.中西医结合心脑血管病杂志.2018,16（1）:40-53.......................................................................................30

[4]宫媛媛，聂波，张红，刘磊，宋连英，潘惠惠，张立苹，周兰珍，康澍，孔令钢，宋志超，杜崇德，蒋根娣，王军.耳穴神门压籽法对偏头痛病人大脑低频振荡振幅影响的研究.中西医结合心血管病杂志，2018，16（3）:276-280.........31

[5]王婕, 吴爱明, 李春红, 陈慧洋, 赵一舟, 赵明镜, 张冬梅, 聂波, 祁轶斐, 成文堃, 任学娇, 刘硕, 娄利霞*. 益气活血方对大鼠心肌梗死边缘区Sigma-1R、SERCA2a、IP3RmRNA表达的影响. 中西医结合心脑血管病杂志, 2018,16(9): 1180-1184.....................................................................................................32

[6]李春红，王婕，吴爱明，娄利霞*.内质网应激与心力衰竭的相关性研究进展.中西医结合心脑血管病杂志, 2018,16(12):1662-1666. .....................................33

[7]张琴,杨欣宇,张晓雨,商洪才. 中药防治蒽环类药物引发心律失常疗效的系统评价[J]. 中国循证医学杂志,2018,18(06):604-609.......................................34

[8]石兆峰,韩松洁,黄涯,何天麦,阿斯亚木·木沙江,商洪才.心血宁治疗心血管疾病的临床证据评价与效应机制[J].世界科学技术-中医药现代化,2018,20(10):1745-1753....................................................................................35

[9]李敏,邱瑞瑾,孙杨,张晓雨,郑蕊,胡嘉元,李承羽,陈诗琪,蒋寅,杨欣宇,石兆峰,韩松洁,何天麦,黄涯,商洪才.稳心颗粒治疗心房颤动临床研究的系统评价[J].世界科学技术-中医药现代化,2018,20(10):1761-1771...............................36

[10]韩松洁,张晓雨,张立晶,商洪才.麝香通心滴丸对PCI术后患者慢血流的临床证据评价[J].世界科学技术-中医药现代化,2018,20(10):1772-1777...........37

[11]李涵,商洪才,孙杨,张晓雨,张明雪.冠心病稳定性心绞痛中医辨治方案的循证优化设计与思考[J].世界科学技术-中医药现代化,2018,20(12):2109-211338

[12]张晓雨,蒋寅,孙杨,刘岩,张立晶,商洪才.冠心病中医药干预时机的循证研究设计与思考[J].世界科学技术-中医药现代化,2018,20(12):2114-2118.......39

[13]胡嘉元,代倩倩,邱瑞瑾,孙杨,张晓雨,田贵华,商洪才.基于终点事件的冠心病心衰中医防治方案循证优化思路和方法[J].世界科学技术-中医药现代化,2018,20(12):2119-2125....................................................................................40[14]李承羽,陈耀龙,胡嘉元,商洪才.冠心病中西医结合临床实践指南研制现状及思考[J].世界科学技术-中医药现代化,2018,20(12):2101-2108...................41

2. 脑血管病方向

[15]杨尚依,商洪才,毕春露,姜旭,杨金娥,张颖. 卒中急性期内抑郁与神经功能缺损程度及血清Hcy、TNF-α、hs-CRP相关性的研究[J].解放军医药杂志,2018,30(11):66-69.............................................................................................42[16]杨尚依,商洪才,张姗,毕春露,姜旭,杨金娥,张颖. 逍遥解郁方对卒中后抑郁患者神经功能及单胺类神经递质分泌的影响[J]. 四川中医,2018,36(10):123-127.........................................................................................43

[17]Tiantian Yang,Qi Guo,Xiaowei Shi,Shuang Wu,Ya Li,Yikun Sun,YizhouZhao,Limin Chai,Yonghong Gao,Lixia Lou,Bin Dong,Lingqun Zhu*.Panax notoginsengsaponins promotes cerebral recovery from ischemic injury by downregulatingLINGO-1 and activating the EGFR/PI3K/AKT signaling pathways in vivo. Journal ofTraditional Chinese Medical Sciences.2018,5, 151-160.......................................................................................................................44

[18]王宏杰，朱陵群*，马超，徐薇薇，陈冬霞，陈丹丹.疏肝解郁胶囊联合草酸艾司西酞普兰治疗抑郁症伴焦虑症的疗效观察.中西医结合心脑血管病杂志.2018,16（17）:2470-2472...............................................................................45

[19]王席玲，赵连山，巫雪飞，王晓芸，朱陵群*.银丹心脑通软胶囊对脑梗死恢复期患者血脂调节作用的临床评价研究.临床医药实践.2018,27(8):565-569.46

[20]周韶爽，高荣，孙琛琛，何芳，武荣荣，吴圣贤*，杨惠民. 丹红注射液治疗缺血性脑卒中病人急性期、恢复期的疗效对比观察.中西医结合心脑血管病杂志.2018,16(15):2123-2127.....................................................................................47

[21]田超，袁梦晨，王晓峰，吴爱明，孙逸坤，高永红. 醒脑开窍药治疗中风病实验研究进展. 中西医结合心脑血管病杂志，2018,16（15）:2158-2161........48

3.临床评价方向

[22]刘智,赵晨,高睿,王祯,王辉,商洪才. 临床研究者依从性不同维度及相关因素分析[J]. 中国循证医学杂志,2018,18(09):979-983.......................................49

[23]邱瑞瑾,孙杨,胡嘉元,李敏,何天麦,黄涯,韩松洁,陈静,商洪才. 临床研究中选择结局指标测量工具的方法[J]. 中国循证医学杂志,2018,18(02):238-243.........................................................................................50

[24]王丽.一位临床实践指南研究者的初心与梦想——访WHO指南实施与知识转化合作中心主任、兰州大学循证医学中心陈耀龙教授[J].中华医学信息导报,2018,33(7):3-4..................................................................................................51[25]邱瑞瑾,陈静,雷翔,赵晨,商洪才,李敏. 引入核心指标集概念构建中医临床疗效模糊综合评价方法[J]. 中药新药与临床药理,2018,29(04):528-534.........................................................................................52[26]张晓雨,陈静,赵晨,商洪才. 真实世界理念下观察性与实验性临床研究协同应用[J]. 中国循证医学杂志,2018,18(04):284-288...........................................53

[27]陈耀龙,胡嘉元,李承羽,杨克虎,李幼平,卞兆祥,吴泰相,王燕平,商洪才. 中国临床实践指南的发展与变革[J]. 中国循证医学杂志,2018,18(08):787-792........................................................................................54[28]雷翔,王晓晖,李静,王蓓,赵晨,喻佳洁,李幼平,吴泰相,卞兆祥,商洪才. 中国临床试验CRO的发展与变革[J]. 中国循证医学杂志,2018,18(08):783-786.........................................................................................55

[29]王晓晖,陈静,李静,王蓓,周琳,李幼平,吴泰相,卞兆祥,商洪才. 中国临床试验实施质量控制的发展与变革[J]. 中国循证医学杂志,2018,18(08):776-782.........................................................................................56

[30]王辉,陈静,李幼平,张永刚,喻佳洁,吴泰相,卞兆祥,商洪才. 中国临床研究伦理的发展与变革[J]. 中国循证医学杂志,2018,18(08):769-775...................57

[31]田然,赵晨,郑颂华,林伟青,杨桢,吴泰相,杨克虎,李幼平,商洪才,吕爱平,卞兆祥. 中医药临床疗效研究报告体系构建过程[J]. 中国循证医学杂志,2018,18(07):651-653.........................................................................................58

[32]赵晨,林伟青,田然,杨桢,吕爱平,商洪才,卞兆祥. 重视临床试验设计,提升中国临床试验质量[J]. 中国循证医学杂志,2018,18(07):645-647...................59

[33]胡嘉元,赵晨,田然,李江,陈耀龙,张晓雨,孙杨,邱瑞瑾,李幼平,田贵华,杨克虎,卞兆祥,商洪才. 中医药临床研究报告规范体系研究[J]. 中国循证医学杂志,2018,18(11):1151-1157.....................................................................................60[34]张晓雨,商洪才. 近十年国内中医药临床研究发展现状及存在的问题[J]. 中医杂志,2018,59(21):1808-1811.........................................................................61

[35]林伟青,田然,赵晨,商洪才,吴泰相,李幼平,卞兆祥. 促进临床试验数据共享,提高临床试验的透明化[J]. 中国循证医学杂志,2018,18(09):893-895.........................................................................................62[36]吴泰相,卞兆祥,李幼平,商洪才,姚新生. 临床试验原始数据透明化与共享:关于医学研究伦理的哲学命题及其对临床试验的意义[J]. 中国循证医学杂志,2018,18(06):538-542.........................................................................................63

[37]吴泰相,米娜瓦尔·阿不都,卞兆祥,商洪才,杨磊,郝园,孔翔瑜,陈硕,李幼平. 基于临床试验注册信息调查影响我国临床试验质量的因素[J]. 中国循证医学杂志,2018,18(06):526-531.................................................................................64

[38]吴泰相,卞兆祥,李幼平,商洪才. 促进我国临床试验数据管理规范化[J]. 中国循证医学杂志,2018,18(06):532-537.............................................................65

[39]陈诗琪,郑蕊,李幼平,商洪才.中药注射剂临床应用存在问题及说明书的相关思考与建议[J].世界科学技术-中医药现代化,2018,20(10):1718-1722.......66

[40]邱瑞瑾,李敏,胡嘉元,黄涯,何天麦,韩松洁,郑蕊,张晓雨,关曼柯,陈静,商洪才.中成药上市后临床安全性评价核心数据集的构建方法探索[J].世界科学技术-中医药现代化,2018,20(10):1723-1728...........................................................67

[41]陈诗琪,郑蕊,李幼平,邝心颖,商洪才.不良反应因果关系判定方法对上市后中成药安全性评价的指导意义[J].世界科学技术-中医药现代化,2018,20(10):1729-1733.....................................................................................68

[42]何天麦,杨欣宇,邱瑞瑾,韩松洁,黄涯,商洪才.丹红注射液对冠心病经皮冠状动脉介入术后内皮功能影响的系统评价[J].世界科学技术-中医药现代化,2018,20(12):2126-2133..........................................................................................69

[43]杨欣宇,邢雁伟,商洪才.丹红注射液对冠心病经皮冠状动脉介入术后炎症因子影响的荟萃分析[J].世界科学技术-中医药现代化,2018,20(12):2134-214.70

[44]李敏,邱瑞瑾,孙杨,张晓雨,郑蕊,胡嘉元,李承羽,陈诗琪,蒋寅,杨欣宇,石兆峰,韩松洁,何天麦,黄涯,商洪才.稳心颗粒治疗心房颤动临床研究的系统评价[J].世界科学技术-中医药现代化,2018,20(10):1761-1771...............................71

[45]邱瑞瑾,李敏,胡嘉元,黄涯,何天麦,韩松洁,郑蕊,张晓雨,关曼柯,陈静,商洪才.中成药上市后临床安全性评价核心数据集的构建方法探索[J].世界科学技术-中医药现代化,2018,20(10):1723-1728...........................................................72

[46]郑蕊,赵晨,陈诗琪,张晓雨,商洪才.精确循证促进中药注射剂合理合法应用的策略与路径[J].世界科学技术-中医药现代化,2018,20(10):1713-1717........73

[47]胡晶,冯硕,李博,张会娜,商洪才.处方序列对称分析在研究中药注射剂不良反应中的应用展望[J].世界科学技术-中医药现代化,2018,20(10):1739-1744.....................................................................................74

[48]陈诗琪,郑蕊,李幼平,邝心颖,商洪才.不良反应因果关系判定方法对上市后中成药安全性评价的指导意义[J].世界科学技术-中医药现代化,2018,20(10):1729-1733.....................................................................................75

[49]郑蕊,陈诗琪,商洪才.中西药物联用安全性评价——“征靶关联法”的探索建立[J].世界科学技术-中医药现代化,2018,20(10):1734-1738.......................76

4.中药药理方向及作用机制方向

[50]Fangchen,Yingkun He,Pengwen Wang*,Peng Wei,Huili Feng,Yingxue Rao,Jing Shi,JinzhouTian.Curcumin can influence synaptic dysfunction in APPswe/PS1dE9 mice.Journalof Traditional Chinese Medical Sciences,2018,5,168-176.......................................................................................77

[51]董云芳，冯慧利，陈芳，盛宁，任映，杨金铎，时晶，田金洲，王蓬文*.金思维对东莨菪碱致记忆障碍小鼠脑胆碱能系统的影响.中国实验动物学报.2018,26(1):107-113............................................................................................78[52]吴艺琼，陈芳，盛宁，任映，杨金铎，王蓬文*.参枝苓口服液对APPswe/PSldE9小鼠学习记忆和突触超微结构的影响.北京中医药大学学报.2018,41(10):821-825.........................................................................................79[53]张建,黄凤珍,张炜,李小军,李玉桑,唐潇旖,胡烨胤,商洪才,唐和斌,田贵华. 豨红通络口服液改善小鼠炎性和神经病理性疼痛的作用研究[J]. 天津中医药,2018,35(05):376-380.........................................................................................80[54]张晓雨,陈诗琪,李承羽,田贵华,赵晨,邱瑞瑾,胡嘉元,郑蕊,孙杨,李敏,陈耀龙,孙鑫,李博,张洪来,卞兆祥,商洪才. 循证中医药学理论研究与应用实践[J]. 中国循证医学杂志,2018,18(01):86-91.......................................................81

[55]黄涯,何天麦,韩松洁,代倩倩,关曼柯,钟长鸣,石兆峰,袁慧婵,商洪才.舒血宁注射液临床证据评价及其效应特点[J].世界科学技术-中医药现代化,2018,20(10):1754-1760.....................................................................................82

[56]蒋寅,商洪才.注射用益气复脉(冻干)治疗冠心病心衰的临床证据及效应机制[J].世界科学技术-中医药现代化,2018,20(12):2141-2144...........................83

[57]石兆峰,韩松洁,黄涯,何天麦,阿斯亚木·木沙江,商洪才.心血宁治疗心血管疾病的临床证据评价与效应机制[J].世界科学技术-中医药现代化,2018,20(10):1745-1753.....................................................................................84

5.药物分析方向

[58]李慧，杨慧，宋柯，白云绮，聂波*.浅谈麻黄与麻黄根的异同.中国现代中药,2018,20(9):1165-1178.......................................................................................85

6.中医理论方法

[59]张晓雨,杨欣宇,张琴,邱瑞瑾,李敏,孙杨,刘硕,商洪才. 方证相应理论的系统生物学研究进展[J]. 辽宁中医杂志,2018,45(06):1335-1337.......................86

[60]赵晨,张晓雨,胡嘉元,靳英辉,思金华,李戈,翟静波,卞兆祥,商洪才. 中医同证候系疾病临床研究母方案设计方法[J]. 中医杂志,2018,59(02):111-115.........................................................................................87[61]邱瑞瑾,张晓雨,李敏,商洪才. 中医证候命名规范化研究在核心指标集构建中的意义及方法[J]. 中华中医药杂志,2018,33(06):2240-2243.......................88

[62]陈诗琪,郑蕊,李幼平,商洪才.中药注射剂临床应用存在问题及说明书的相关思考与建议[J].世界科学技术-中医药现代化,2018,20(10):1718-1722.....................89

7肾脏病、内分泌、风湿免疫方向

[63] Qi-Yan Zheng#, Wei-JingLiu#,Wei-Wei, Sun , Yao-Xian Wang ,  Hong-Fang  Liu , Lu-Ying Sun* :The efficacy and safety of Chinese herbal medicine combined  with ACEI/ARBfor treatment of incipient diabetic nephropathy:  A meta-analysis. TMR Integrative Medicine.2018 , 2(1): 07-29...........................................................................................................................90

[64] 李婷婷,王淑君,杨陈,吴洪銮员，李志航，刘华锋*，刘伟敬*: TFEB调控——肾脏疾病治疗的新思路. 中国病理生理杂志 Chinese Journal of Pathophysiology，2018,34(4) : 754-759..........................................................91

[65]陈观生，贾奇，马雷雷，姜韩雪，侠晨辉，朱泽兵，刘伟敬*，刘玉宁*.蝉花菌丝对Ang II作用下的肾小管上皮细胞细胞外基质分泌的影响*.中国中西医结合肾病杂志2018,19（9）：764-767..................................................................92

[66]吴立坤,刘玉宁*，刘伟敬*.中西结合用于肾病的专利申请现状分析.中国中西医结合肾病杂志,2018,19(8),733-734...............................................................93

[67]贾奇，邓健锟，冯振东，韩雪婷，侠晨辉，朱泽兵，刘玉宁*，刘伟敬.蝉花通过抑制肾小管NADPH氧化酶／氧化应激治疗糖尿病肾病的研究.中国中西医结合肾病杂志,2018,19(12),1041-1045.....................................................................94

[68]黄为钧，赵进喜，王世东*，傅强，宫晴，张华，吴文静，申子龙.基于PI3K/Akt信号通路探索益气活血祛风通络法治疗糖尿病肾病的作用机制[J].环球中医药杂志,2018,11（8）:1196-1203...............................................................................95

[69]邓培颖，李雪，韦翊，董玢，金秋硕，柴利民*.补肾生血解毒方及拆方对免疫介导再生障碍性贫血小鼠T淋巴细胞增殖和分化的影响.中华中医药杂志，2018,33（7）:3014-3018...........................................................................................96

[70]吴立坤,刘玉宁*，刘伟敬*.以专利申请的角度详细探究中西药结合治疗肾病中药物和治则的运用情况.综合医学.2018,38:333-334.......................................97